Page 30 - 76_03
P. 30

CONSUELO BOTICARIO Y MARÍA CASCALES  AN. R. ACAD. NAC. FARM.

 4. Wang, G. L. & Semenza, G. L. (1995) Purification and characterization of hy-
        poxia-inducible factor 1. J. Biol. Chem. 270: 1230-1237.

 5. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:
        721-732.

 6. Guertin, D. A. & Sabatini, D. M. (2005) An expanding role for mTOR in can-
        cer. Trends Mol. Med. 11: 353-361.

 7. Brahimi-Horn, C., Mazure, N. & Pouysegur, J. (2005) Signaling via the hypox-
        ia-inducible factor-1alpha requires multiple posttranslational modifications.
        Cell. Signal. 17: 1-9.

 8. Schofield, C. J. & Ratcliffe, P. J. (2005) Signalling hypoxia by HIF hydroxylases.
        Biochem. Biophys. Res. Commun. 338: 617-626.

 9. Kaelin, Jr. W. G. (2003) The von Hippel-Lindau gene, kidney cancer, and oxy-
        gen sensing. J. Am. Soc. Nephrol. 14: 2703-2711.

10. Coleman, M. L. & Ratcliffe, P. J. (2010) Angiogenesis escape from hypoxia.
        Nature Med. 15: 491-493.

11. Maxwell, P. H. (2005) The HIF pathway in cancer. Semin. Cell. Dev. Biol. 16:
        523-530.

12. Aprelikova, O., Chandramouli, G. V., Wood, M. et al. (2004) Regulation of HIF
        prolyl hydroxylases by hypoxia-inducible factors. J. Cell. Biochem. 92: 491-501.

13. Nakayama, K., Frew, I. J., Hagensen, M. et al. (2004) Siah2 regulates stability
        of prolyl-hydrolases, controls HIF alpha abundance, and modulates physiolog-
        ical responses to hypoxia. Cell. 117: 941-952.

14. Pouysségur, J. & Mechta-Grigoriou, F. (2006) Redox regulation of the hypoxia-
        inducible factor. Biol. Chem. 387: 1337-1346.

15. Brahimi-Horn, C. & Pouyssegur, J. (2009) HIF at a glance. J. Cell. Sci. 122: 1055-
        1057.

16. Manalo, D. J., Rowan, T., Lavoie, L. et al. (2005) Transcriptional regulation of
        vascular endothelial cell responses to hypoxia by HIF-1. Blood. 105: 659-669.

17. Gatenby, R. A. & Gillies, R. J. (2004) Why do cancers have high anaerobic gly-
        colysis? Nat. Rev. Cancer. 4: 891-899.

18. Walenta, S. & Mueller-Klieser, V. F. (2004) Lactate: mirror and motor of tumor
        malignancy. Semin. Radiat. Oncol. 14: 267-274.

19. Wykoff, C. C., Beasley, N. J., Watson, P. H. et al. (2000) Hypoxia-inducible ex-
        pression of tumor-associated carbonic anhydrases. Cancer Res. 60: 7075-7083.

20. Semenza, G. L. (2010) HIF-1 upstream and downstream of cancer metabolism.
        Curr. Opin. Genet. Der. 20: 51-56.

21. Onnis, B., Rapisarda, A. & Melillo, G. (2009) Development of HIF1 inhibitors
        for cancer therapy. J. Cell Mol. Med. 13: 2780-2786.

22. Brown, J. M. & Wilson, W. R. (2004) Exploiting tumour hypoxia in cancer treat-
        ment. Nat. Rev. Cancer. 4: 437-447.

23. Melillo, G. (2006) Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol.
        Cancer Res. 4: 601-605.

24. Giaccia, A., Siim, B. G. & Johnson, R. S. (2003) HIF-1 as a target for drug de-
        velopment. Nat. Rev. Drug Discov. 2: 803-811.

25. Young, R. M., Wang, S. J., Gordan, J. D. et al. (2008) Hypoxia-mediated selec-
        tive mRNA translation by an internal ribosomal entry site-independent mecha-
        nism. J. Biol. Chem. 283: 16309-16319.

406
   25   26   27   28   29   30   31   32   33   34   35